Jove
Visualize
Contact Us

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FOLR1-targeted actinium-225-based alpha-particle therapy eliminates ovarian cancer.

Science advances·2026
Same author

Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cells.

Cancer immunology research·2026
Same author

Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer.

Nature biomedical engineering·2026
Same author

Estrogen receptor β target gene expression reveals novel repressive functions in aggressive breast cancer.

NPJ breast cancer·2026
Same author

FOLR1-targeted Actinium-225-based Alpha-particle Therapy Eliminates Ovarian Cancer.

bioRxiv : the preprint server for biology·2025
Same author

Preliminary evaluation of the safety and feasibility of toll-like receptor ligand CB101 combined with hypofractionated radiation therapy in canine head and neck cancer: a pilot study.

Veterinary oncology (London, England)·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 19, 2026

A Computational Modeling Approach to Investigate the Influence of Hyperthermia on the Tumor Microenvironment
10:23

A Computational Modeling Approach to Investigate the Influence of Hyperthermia on the Tumor Microenvironment

Published on: December 1, 2023

Modulating the tumor microenvironment to increase radiation responsiveness.

Jayashree Karar1, Amit Maity

  • 1Department of Radiation Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.

Cancer Biology & Therapy
|October 14, 2009
PubMed
Summary
This summary is machine-generated.

Modulating the tumor microenvironment (TME) can enhance cancer radiosensitivity. Targeting factors like vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) shows promise in preclinical models for improving radiation therapy outcomes.

More Related Videos

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids
05:39

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids

Published on: April 5, 2024

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Related Experiment Videos

Last Updated: Jun 19, 2026

A Computational Modeling Approach to Investigate the Influence of Hyperthermia on the Tumor Microenvironment
10:23

A Computational Modeling Approach to Investigate the Influence of Hyperthermia on the Tumor Microenvironment

Published on: December 1, 2023

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids
05:39

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids

Published on: April 5, 2024

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Area of Science:

  • Oncology
  • Radiation Oncology
  • Cancer Biology

Background:

  • Tumor radiosensitivity is influenced by intrinsic and extrinsic factors within the tumor microenvironment (TME).
  • Tumor oxygenation is a critical extrinsic factor; hypoxic cells require significantly higher radiation doses for equivalent cell killing.
  • Other TME components influencing radiosensitivity include stromal cell response and expression of factors like vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1 (HIF-1).

Purpose of the Study:

  • To review current strategies for modulating the TME to enhance tumor radiosensitivity.
  • To explore the mechanisms by which agents targeting VEGF, HIF-1, and epidermal growth factor receptor (EGFR) may improve radiation therapy efficacy.
  • To highlight the need for clinical data validating TME modulation in radiosensitization.

Main Methods:

  • Review of preclinical evidence and clinical data on agents targeting the TME.
  • Analysis of mechanisms of action for VEGF inhibitors, HIF-1 targeting agents, and EGFR inhibitors in the context of radiation therapy.
  • Examination of downstream pathways such as PI3K/Akt involved in EGFR-mediated radiosensitization.

Main Results:

  • Preclinical studies suggest VEGF inhibition can improve local control post-radiation through various mechanisms, including vascular normalization and increased oxygenation.
  • Agents targeting HIF-1 also demonstrate improved local control in preclinical models, potentially via indirect VEGF inhibition or other pathways.
  • EGFR inhibitors, like cetuximab, have shown improved outcomes in head and neck cancer patients when combined with radiation, with preclinical data suggesting enhanced intrinsic and extrinsic radiosensitivity.

Conclusions:

  • Modulating the TME offers a promising strategy to enhance tumor radiosensitivity and improve radiation therapy outcomes.
  • Targeting VEGF, HIF-1, and EGFR pathways are key areas of investigation for radiosensitization.
  • Further clinical validation is crucial to confirm the role of TME modulation in radiosensitization and to optimize therapeutic strategies.